20th Jul 2020 20:03
Angle PLC - liquid biopsy company - Says University of Southern California publishes results of work undertaken in metastatic breast cancer highlighting advantages of a Parsortix liquid biopsy compared to standard of care tissue biopsy. USC showed that potential actionable therapeutic targets were found in the Parsortix liquid biopsy that were missed in the tissue biopsy of a single metastatic site. "This study demonstrates key capabilities of Parsortix for metastatic breast cancer, which is the area of focus for Angle's FDA submission currently in preparation with the aim of submission later this quarter," said Angle.
Current stock price: 56.00 pence
Year-to-date change: down 11%
By Lucy Heming;Â [email protected]
Copyright 2020 Alliance News Limited. All Rights Reserved.
Related Shares:
Angle